



Global Programme to Eliminate Lymphatic Filariasis

Annual Report on Lymphatic Filariasis 2003



For further information about lymphatic filariasis and to order additional copies of this publication at no charge, please contact:

CDS information Resource Centre
World Health Organization
1211 Geneva 27, Switzerland
Fax: +41 22 791 42 85
e-mail: cdsdoc@who.int

<http://www.who.int/infectious-disease-news>

Credit for the photos:

- *top*: WHO/P. Viro
- *bottom*: WHO/R. Davies

© **World Health Organization 2005**

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France.



World Health
Organization



AFUTUREFREEOF LF
Global Alliance

Global Programme to Eliminate Lymphatic Filariasis

Annual Report on Lymphatic Filariasis 2003



ACKNOWLEDGEMENTS

This report is made up of contributions from WHO staff and various partners involved in the Global Programme to Eliminate Lymphatic Filariasis. Its preparation was coordinated by Dr Francesco Rio.

WHO headquarters Geneva:

Dr Gautam Biswas, Dr Pierre Brantus,
Mr Christopher Maddock, Ms Claire Preaud,
Dr Francesco Rio, Dr Sergio Yactayo and
Dr Nevio Zagaria

WHO Regional Office for Africa:

Dr Likezo Mubila and Dr Jean-Baptiste ROUNGOU

WHO Regional Office for the Americas:

Dr John Ehrenberg

WHO Regional Office for the Eastern Mediterranean:

Dr Zoheir Hallaj and Dr Nikolai Neouimine

WHO Regional Office for South-East Asia:

Dr Derek Lobo and Dr E. Padmasiri

WHO Regional Office for the Western Pacific:

Dr Kazuyo Ichimori and Dr Kevin Palmer

The aim of the report is to share information among all actors involved in the elimination efforts and other interested parties. The data presented are supplied largely by national programme managers who are at the heart of the global elimination operations. We wish to express our gratitude to them and their staff for their crucial contribution.

Additional thanks are due to the following specific partners for their contributions: Dr Susan Girois, Handicap International; Mr Ken Gustavsen, Merck & Co., Inc.; Ms Minne Iwamoto, GlaxoSmithKline; Dr Mary-Ellen Kitler, WHO; Professor David Molyneux, Liverpool Lymphatic Filariasis Support Centre; Dr Eric Ottesen, Emory University Lymphatic Filariasis Support Centre; Dr Bjørn Thylefors, Mectizan® Donation Program; Dr Nana Twum-Danso, Mectizan® Donation Program and Mr Andy Wright, GlaxoSmithKline.

Technical editor: Barbara Campanini

Editorial assistance:

Ms Tabinda Faizi and Ms Rosemary Wakeling,
WHO Headquarters

Layout: www.services-concept.ch

Photographs are the copyright of
the World Health Organization

In addition, we would like to thank the Chairs of the regional Programme Review Groups as follows:

African PRG:

Dr Johnny Gyapong

American PRG:

Dr John Ehrenberg (acting Chair pending appointment)

Eastern Mediterranean PRG:

Dr Maged El Setouhy

Mekong-Plus PRG:

Professor Dr Dato C.P. Ramachandran

PacCARE PRG:

Dr Joe Koroivuetu

South Asia PRG:

Professor Mahroof Ismail

Additional copies of this publication are available at no charge from:

Communicable Diseases Information Resource Centre
World Health Organization, 1211 Geneva 27, Switzerland
Fax +41 (0)22 791 42 85, e-mail cdsdoc@who.int
www.who.int/infectious-disease-news

C O N T E N T S

Programme highlights.....	5
Introduction.....	7
CHAPTER 1 PROGRESS OF THE GLOBAL PROGRAMME TO ELIMINATE LYMPHATIC FILARIASIS.....	9
Mapping the distribution of lymphatic filariasis.....	9
Surveillance of the safe use of co-administered drugs.....	11
Supplying quality medicines for filariasis elimination.....	13
<i>GlaxoSmithKline</i>	13
<i>Merck & Co., Inc. — Mectizan® Donation Program</i>	13
<i>Diethylcarbamazine citrate</i>	13
Mid-term assessment of microfilaraemia reduction.....	17
<i>African PRG</i>	17
<i>American PRG</i>	18
<i>Eastern Mediterranean PRG</i>	18
<i>Mekong-Plus PRG</i>	19
<i>PacCARE PRG</i>	19
<i>South Asia PRG</i>	19
Social mobilization.....	23
Advocacy.....	24
Prevention of disability.....	25
Training and capacity-building.....	27
Research.....	28
<i>Ivermectin and albendazole</i>	28
<i>DEC and albendazole</i>	28
<i>Development of evidence-based guidelines for elimination strategies using available drug combinations</i>	28
<i>Development of improved drug delivery strategies, especially in urban settings</i>	28
<i>Community-based management of lymphoedema and adenolymphangitis</i>	28
<i>WHO/TDR Workshop on Prevention of Disability Associated with Lymphatic Filariasis</i>	29
<i>Rapid assessment procedures for mapping loiasis</i>	29

	Report of the Technical Advisory Group on Lymphatic Filariasis, 2003 ..	29
	<i>Monitoring and evaluation</i>	30
	<i>Review of completed, ongoing and future research</i>	31
	<i>Chemotherapy</i>	31
	<i>Strategies for implementing prevention of disability</i>	32
	<i>Synergies with soil-transmitted helminth control</i>	32
	<i>Social mobilization</i>	32
	<i>Strategic plan</i>	32
CHAPTER 2	GLOBAL ALLIANCE TO ELIMINATE LYMPHATIC FILARIASIS	33
	Partnership.....	33
	What is the Global Alliance?.....	33
	Update on the Global Alliance.....	34
CHAPTER 3	PROGRAMME IMPLEMENTATION	35
	Regional Programme Review Group perspectives and country profiles...	35
	<i>African PRG</i>	35
	<i>American PRG</i>	59
	<i>Eastern Mediterranean PRG</i>	67
	<i>Mekong-Plus PRG</i>	75
	<i>PacCARE PRG</i>	91
	<i>South Asia PRG</i>	107
CHAPTER 4	FINANCIAL ASPECTS	117
	Financial resources and expenditures.....	117
	Ways and means of achieving targets.....	117
	Department for International Development of the United Kingdom.....	117
	Bill and Melinda Gates Foundation.....	118
	Australian Agency for International Development.....	118
CHAPTER 5	THE GLOBAL INITIATIVE – THE WAY FORWARD	119
CHAPTER 6	FURTHER DOCUMENTATION	123

ANNEXES

Annex 1	Reports of major international support and partners.....	125
Annex 2	Revised annual report form.....	131
Annex 3	List of LF-endemic countries and territories by Programme Review Group.....	143
Annex 4	Abbreviations and definitions.....	145

预览已结束，完整报告链接和二维码

<https://www.yunbaogao.cn/report/index/report?re>